SG11202112412QA - Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors - Google Patents
Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitorsInfo
- Publication number
- SG11202112412QA SG11202112412QA SG11202112412QA SG11202112412QA SG11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA SG 11202112412Q A SG11202112412Q A SG 11202112412QA
- Authority
- SG
- Singapore
- Prior art keywords
- egfr
- tyrosine kinase
- kinase inhibitors
- combination therapies
- bispecific anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962847605P | 2019-05-14 | 2019-05-14 | |
PCT/IB2020/054594 WO2020230091A1 (en) | 2019-05-14 | 2020-05-14 | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202112412QA true SG11202112412QA (en) | 2021-12-30 |
Family
ID=78716450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202112412QA SG11202112412QA (en) | 2019-05-14 | 2020-05-14 | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3968985A4 (en) |
JP (1) | JP2022531980A (en) |
KR (1) | KR20220010731A (en) |
CN (1) | CN113840601A (en) |
AU (1) | AU2020275272A1 (en) |
BR (1) | BR112021022828A2 (en) |
CA (1) | CA3140360A1 (en) |
EA (1) | EA202193117A1 (en) |
IL (1) | IL287962A (en) |
MA (1) | MA55978A (en) |
MX (1) | MX2021013955A (en) |
SG (1) | SG11202112412QA (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
TW200940064A (en) * | 2008-03-06 | 2009-10-01 | Genentech Inc | Combination therapy with C-MET and EGFR antagonists |
MX353144B (en) * | 2010-04-20 | 2017-12-20 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof. |
US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
HUE052548T2 (en) * | 2012-11-21 | 2021-05-28 | Janssen Biotech Inc | Bispecific egfr/c-met antibodies |
AR111469A1 (en) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | COME OUT OF AN AMINOPIRIDINE DERIVATIVE COMPOUND, A CRYSTAL FORM OF THE SAME, AND A PROCESS TO PREPARE THE SAME |
-
2020
- 2020-05-14 EA EA202193117A patent/EA202193117A1/en unknown
- 2020-05-14 CN CN202080035662.6A patent/CN113840601A/en active Pending
- 2020-05-14 KR KR1020217040739A patent/KR20220010731A/en unknown
- 2020-05-14 JP JP2021567974A patent/JP2022531980A/en active Pending
- 2020-05-14 MA MA055978A patent/MA55978A/en unknown
- 2020-05-14 EP EP20806609.2A patent/EP3968985A4/en active Pending
- 2020-05-14 SG SG11202112412QA patent/SG11202112412QA/en unknown
- 2020-05-14 CA CA3140360A patent/CA3140360A1/en active Pending
- 2020-05-14 MX MX2021013955A patent/MX2021013955A/en unknown
- 2020-05-14 BR BR112021022828A patent/BR112021022828A2/en unknown
- 2020-05-14 AU AU2020275272A patent/AU2020275272A1/en active Pending
-
2021
- 2021-11-09 IL IL287962A patent/IL287962A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3968985A1 (en) | 2022-03-23 |
MX2021013955A (en) | 2022-03-11 |
MA55978A (en) | 2022-03-23 |
IL287962A (en) | 2022-01-01 |
CA3140360A1 (en) | 2020-11-19 |
CN113840601A (en) | 2021-12-24 |
JP2022531980A (en) | 2022-07-12 |
EP3968985A4 (en) | 2023-07-26 |
KR20220010731A (en) | 2022-01-26 |
AU2020275272A1 (en) | 2021-12-02 |
BR112021022828A2 (en) | 2022-04-12 |
EA202193117A1 (en) | 2022-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210304A1 (en) | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors | |
EP3399968B8 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
EP3648753A4 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
PH12018500709A1 (en) | Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use | |
SG11202010893WA (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
PH12018500710A1 (en) | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use | |
IL285718A (en) | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies | |
TN2017000470A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens. | |
MX2017004311A (en) | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof. | |
MX358728B (en) | Humanized pan-her antibody compositions. | |
IL279251A (en) | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies | |
TN2019000161A1 (en) | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof | |
HK1250736A1 (en) | Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies | |
ZA202006247B (en) | Bispecific egfr/cd16 antigen-binding protein | |
IL279325A (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
IL287962A (en) | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors | |
EP4004053A4 (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
EP3328426B8 (en) | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) | |
EP3604312A4 (en) | Fourth-generation egfr tyrosine kinase inhibitor | |
IL308225A (en) | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors | |
EA201792249A1 (en) | COMBINED THERAPY OF MALIGNANT TUMOR |